Oxaliplatin-related side effects: Characteristics and management

Seminars in Oncology

Volumn 29, Issue 5, 2002, Pages 11-20

  Cassidy, Jim ^a,b   Misset, Jean Louis ^a,b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIAMINOCYCLOHEXANE; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GLUCOCORTICOID; IRINOTECAN; OXALIPLATIN; PLATINUM DERIVATIVE; SEROTONIN 3 ANTAGONIST; TAXANE DERIVATIVE; TETRAPLATIN; THYMIDYLATE SYNTHASE INHIBITOR;

ADVANCED CANCER; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; AWARENESS; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HEALTH PRACTITIONER; HUMAN; LIVER TOXICITY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; HUMANS; ORGANOPLATINUM COMPOUNDS;

EID: 0037010085     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(02)90016-3     Document Type: Article

References (39)

1. Raymond E, Faivre S, Woynarowski J, et al: Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 25:4-12, 1998 (suppl 5)
2. Raymond E, Buquet-Fagot C, Djelloul S, et al: Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 8:876-885, 1997
3. Zeghari-Squalli N, Raymond E, Cvitkovic E, et al: Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 5:1189-1196, 1999
4. Faivre S, Raymond E, Woynarowski J, et al: Supraadditive effect of 2',2'-difluorordeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 44:117-123, 1999
5. de Gramont A, Vignoud J, Tournigand C, et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33:214-219, 1997
6. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
7. Lévi F, Zidani R, Misset J-L, for the International Organization for Cancer Chronotherapy: Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350:681-686, 1997
8. Lévi FA, Zidani R, Vannetzel J-M, et al: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial. J Natl Cancer Inst 86:1608-1617, 1994
9. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000
10. Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al: Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 14:2950-2958, 1996
11. Becouarn Y, Ychou M, Ducreux M, et al: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 16:2739-2744, 1998
12. Goldwasser F, Gross-Goupil M, Tigaud J, et al: Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients. Ann Oncol 11:1463-1470, 2000
13. Wasserman E, Cuvier C, Lokiec F, et al: Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics. J Clin Oncol 17:1751-1759, 1999
14. Scheithauer W, Kornek G, Raderer M, et al: Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol 17:902-906, 1999
15. Mathé G, Kidani Y, Triana K, et al: A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (I-OHP). Biomed Pharmacother 40:372-376, 1986
16. Extra JM, Espie M, Calvo F, et al: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299-303, 1990
17. Gamelin E, Boisdron-Celle M, Allain P, et al: Pharmacokinetic interference between oxaliplatin (L-OHP) and fluorouracil (5-FU): delayed 5-FU metabolism inhibition by LOHP. Proc Am Assoc Cancer Res 38:A1500, 1997 (abstr)
18. Joel S, Richards F, Seymour M: Oxaliplatin (L-OHP) does NOT influence the pharmacokinetics of 5-fluorouracil (5-FU). Proc Am Soc Clin Oncol 19:192a, 2000 (abstr 748)
19. McLeod H, Sludden J, Murray G, et al: Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. Br J Cancer 77:461-465, 1998
20. Harris B, Song R, Soong S, et al: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-flourouracil by protracted continuous infusion. Cancer Res 50:197-201, 1990
21. Machover D, Diaz-Rubio E, de Gramont A, et al: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7:95-98, 1996
22. Brienza S, Vignoud J, Itzhaki M, et al: Oxaliplatin (LOHP): global safety in 682 patients (pts). Proc Am Soc Clin Oncol 14:A209, 1995 (abstr 513)
23. de Gramont A, Figer A, Seymour M, et al: A randomized trial of leucovorin (LV) and 5-fluorouracil (5-FU) with or without oxaliplatin in advanced colorectal cancer. Proc Am Soc Clin Oncol 17:257a, 1998 (abstr 985)
24. Massari C, Brienza S, Rotarski M, et al; Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol 45:157-164, 2000
25. Misset JL, Brienza S, Taamma A, et al: Pharmacokinetics, urinary and fecal excretion of oxaliplatin in cancer patients (pts). Proc Am Assoc Cancer Res 37:AI252, 1996
26. Graham M, Lockwood G, Greenslade D, et al: Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 6:1205-1218, 2000
27. O'Rourke Tj, Weiss GR, New P, et al; Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812). Anticancer Drugs 5:520-526, 1994
28. Schilder RJ, LaCreta FP, Perez RP, et al: Phase-I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res 54:709-717, 1994
29. Luo F, Wyrick S, Chaney S: Comparative neurotoxicity, of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model. Cancer Chemother Pharmacol 44:29-38, 1999
30. Graham M, Lockwood G, Greenslade D, et al: Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 6:1205-1218, 2000
31. Taieb S, Freyer G, Rambaud L, et at: Central neurotoxicity induced by oxaliplatin: Report on 4 cases. Proc Am Soc Clin Oncol 19:313a, 2000 (abstr 1234)
32. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000
33. Lévi F, Dogliotti L, Perpoirit B, et al: A multicenter phase II trial of intensified chronotherapy with oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) in patients (Pts) with previously untreated metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 16:266a, 1997 (abstr)
34. Degardin M, Nguyen K-T, Carlier D, Moreau L, et al: Comparative study of the ototoxicity of cisplatin and oxaliplatin in patients with mature epidermoid carcinoma of the upper respiratory tract. JFORL 46:292-296, 1997
35. O'Connell M: A phase III, trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer: A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 63:1026-1030, 1989 (suppl 6)
36. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup sttidy. J Clin Oncol 15:808-815, 1997
37. Madajewicz S, Petrelli N, Rustum Y, et al: Phase I-II trial of high dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res 44:4667-4669, 1984
38. Maindrault-Goebel F, de Gramont A, Louver C, et al: High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37:1000-1005, 2001
39. Buechele T, Schoeber C, Kroening H, et al: Weekly high dose (HD) 5-fluorouracil (5-FU) and folinic acid (FA) with addition of oxaliplatin (LOHP) after documented progression under high dose infusional 5-FU/FA in patients (PTS) with advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 17:287a, 1998 (abstr 1106)